Cargando…
Integrated multi‐omics data reveals the molecular subtypes and guides the androgen receptor signalling inhibitor treatment of prostate cancer
Autores principales: | Meng, Jialin, Lu, Xiaofan, Jin, Chen, Zhou, Yujie, Ge, Qintao, Zhou, Jun, Hao, Zongyao, Yan, Fangrong, Zhang, Meng, Liang, Chaozhao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694501/ https://www.ncbi.nlm.nih.gov/pubmed/34936729 http://dx.doi.org/10.1002/ctm2.655 |
Ejemplares similares
-
Tumor immune microenvironment-based classifications of bladder cancer for enhancing the response rate of immunotherapy
por: Meng, Jialin, et al.
Publicado: (2021) -
Protective trend of anti-androgen therapy during the COVID-19 pandemic: A meta-analysis
por: Meng, Jialin, et al.
Publicado: (2022) -
Overexpression of DDX49 in prostate cancer is associated with poor prognosis
por: Tao, Junyue, et al.
Publicado: (2023) -
Molecular classifications of prostate cancer: basis for individualized risk stratification and precision therapy
por: Ge, Qintao, et al.
Publicado: (2023) -
Characterization of the prognostic values and response to immunotherapy/chemotherapy of Krüppel‐like factors in prostate cancer
por: Meng, Jialin, et al.
Publicado: (2020)